

About SomaLogic

SomaLogic was founded in 2000 by Larry Gold, with the goal of improving the quality of life of every individual by transforming how health was assessed and managed, based on the precise measurement of changes in the body's proteins.

Our Vision

Empowering a healthier world — one protein scan at a time

Our Mission

We scan the living data stream of human proteins with greater precision, sensitivity and scale than anybody in the world, and translate it into actionable insights for every seeker and enabler of human health.

Notable Facts

- Privately-held biotechnology company
- Based in Boulder, Colorado
- Larry Gold, Ph.D., *Founder and Chairman of the Board*
- Roy Smythe, M.D., *Chief Executive Officer*
- ~200 employees worldwide
- >600 issued and pending patents
- >200 scientific publications from SomaLogic and third-party users

Proteins are the key to understanding and managing health and disease

Proteins (e.g. enzymes, hormones, antibodies, drug receptors, etc.) give our cells structure, guide development, allow the body to move, help fight infection, transport molecules such as oxygen, and regulate complex systems such as blood sugar and mood. The levels of proteins within various parts of the body are constantly changing in response to factors such as diet, aging, drug treatments, microorganisms, and stress. These changes in protein levels provide meaningful insights into a person's state of health and wellness at any specific time and can rapidly determine whether health interventions are working.

The SomaScan® Platform: from protein measurements to precision health information

There are thousands of proteins circulating within the body at any given time, and they are present at vastly different concentrations. SomaLogic's proprietary, SomaScan® Assay is the only proteomic technology that can measure broadly (~5000 proteins simultaneously), deeply (high- and low-abundance proteins), and rapidly (high throughput) in a small sample volume.

SomaLogic has performed the SomaScan Assay on hundreds of thousands of annotated samples (with associated clinical information), evaluating protein levels in individuals with and without a number of health, wellness and disease conditions and characteristics. By doing this, and by virtue of the strong biological signals that thousands of proteins provide, we have developed a number of current state and future predictive state tests for health, wellness and disease. These SomaSignal™ tests rely on sophisticated mathematical models that we have created for each condition or characteristic in question.

Selected Publications:

1. Ganz, P *et al.* (2016) "Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease." [*Journal of the American Medical Association* **315**\(23\): 2532-2541.](#)
2. Ngo, D *et al.* (2016) "Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease." [*Circulation* **134**\(4\): 270-285.](#)
3. Jacob, J *et al.* (2017) "Application of large scale aptamer-based proteomic profiling to "planned" myocardial infarctions." [*Circulation* **137**\(12\): 1270-1277.](#)
4. Williams, SA *et al.* (2018) "Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of Torcetrapib." [*Circulation* **137**\(10\): 999-1010.](#)
5. Benson, MD *et al.* (2018) "Genetic architecture of the cardiovascular risk proteome." [*Circulation* **137**\(11\): 1158-1172.](#)
6. Sun, BB *et al.* (2018) "Genomic atlas of the human plasma proteome." [*Nature* **558**: 73-79.](#)
7. Emilsson, V *et al.* (2018) "Co-regulatory networks of human serum proteins link genetics to disease." [*Science* **361**\(6404\): 769-773.](#)

Website: www.somalogic.com

Twitter: www.twitter.com/somalogic

LinkedIn: www.linkedin.com/company/somalogic

Press contact: mediacontact@somalogic.com